Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3497969 | 1.00 | MAPK1 (0.42) | MAPK1KDM4EALDH1A1POLBGAA | |
| SCHEMBL3499933 | 1.00 | MAPK1 (0.42) | MAPK1KDM4EALDH1A1POLBGAA | |
| SCHEMBL3499166 | 1.00 | MAPK1 (0.42) | MAPK1KDM4EALDH1A1POLBGAA | |
| SCHEMBL581068 | 0.79 | TDP1 (0.44) | MAPK1KDM4EALDH1A1POLBGAA | |
| SCHEMBL4505964 | 0.79 | TDP1 (0.44) | MAPK1KDM4EALDH1A1POLBGAA | |
| Hydrochloric Acid SCHEMBL4504270 | 0.78 | TDP1 (0.44) | MAPK1KDM4EALDH1A1POLBGAA | |
| SCHEMBL8209905 | 0.76 | KDM4E (0.42) | MAPK1KDM4EALDH1A1POLBGAA | |
| SCHEMBL1039190 | 0.76 | KDM4E (0.42) | MAPK1KDM4EALDH1A1POLBGAA | |
| SCHEMBL9965883 | 0.76 | KDM4E (0.42) | MAPK1KDM4EALDH1A1POLBGAA | |
| SCHEMBL27853017 | 0.74 | KDM4E (0.39) | MAPK1KDM4EALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120584-B1 | SILYLATED PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20100093665-A1 | SILYLATED PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2010-04-15 | — | — | US | disclosed |
| WO-2008085301-A1 | SILYLATED PIPERIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093665-A1 | SILYLATED PIPERIDINE DERIVATIVES | PSEN1, PSEN2, SRM | MAPK1 1936/4885KDM4E 2685/4885ALDH1A1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.